Videos

Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.

Maroney discussed the pharmacist’s role in patient education, safe medication management, and incorporating broader treatment strategies into individualized mental health care plans.

This week’s episode covers Marty Makary’s resignation as FDA commissioner, evolving hepatitis B vaccination efforts, and new FDA approvals in asthma and precision oncology.

Securing executive buy-in, building multidisciplinary coalitions, and targeting inappropriate antiplatelet use are among the most critical steps in implementing antithrombotic stewardship programs.

Learn how clinicians tailor add-on lipid therapies—PCSK9s, ezetimibe, bempedoic acid—using shared decisions, follow-up, and statin myths.

Please paste the article text (or a link/excerpt). I’ll generate an SEO-friendly meta description (≤24 words, ≤150 characters) in present tense.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the safety profile of Levorphanol compared with methadone, including potential reductions in risks such as accumulation, QT prolongation, and drug interactions, as well as its implications for clinical workflows and the pharmacist’s role in supporting safe opioid rotation, monitoring, and patient counseling.

Darren Triller, PharmD, makes the case for system-level solutions over individual clinical effort, introducing the ADAPT framework

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and examines how levorphanol compares to methadone in pharmacology and clinical efficacy, as well as the key evidence supporting its use and the practical barriers clinicians face when transitioning between the two agents in complex pain management.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the clinical scenarios and patient populations that prompted the consideration of levorphanol as a methadone-sparing option in complex pain management.

Pharmacy technicians are essential for navigating access barriers, addressing misconceptions, and supporting adherence in obesity care.

Immunotherapy strains budgets: copays, toxicity, and how pharmacists use NCCN evidence blocks to steer value-based cancer care.

Pharmacists tackle formulary limits, shortages, and EHR lag to streamline endometrial cancer immunotherapy, including quick sub-Q dosing.

Pharmacy technicians are increasingly central to obesity care, supporting medication access, workflow efficiency, and patient engagement in ambulatory settings.

Technician-led strategies are accelerating antiretroviral therapy access and improving long-term adherence for patients with HIV.

Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on strategies to improve OTC counseling through clear and accessible communication, considerations for high-risk patient populations such as older adults and those with chronic conditions, and emerging trends shaping the future of OTC care and the expanding role of pharmacy technicians in patient education.

Learn how CAC scores, PREVENT ASCVD, and Lp(a) reshape risk talks—help pharmacists personalize statins, targets, and follow‑up.

Learn how CAC scans, PREVENT ASCVD scoring, and Lp(a) testing sharpen risk talks and guide statin choices in pharmacy practice.

Education, safety protocols, and evolving responsibilities are transforming the role of pharmacy technicians in cancer care.

Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on how pharmacy technicians can recognize when patients should be referred to a pharmacist or physician instead of self-treating with OTC products, and how to help patients avoid risks associated with combination products such as duplicate ingredients.

New CMS prior authorization timelines highlight major infrastructure gaps while underscoring the link between access, affordability, and medication adherence.

FDA approval of orforglipron may expand access to obesity treatment by offering a more convenient oral GLP-1 therapy option.

Explore evolving endometrial cancer treatments: HER2-targeted trastuzumab, ADCs, and immunotherapy sequencing, plus NCCN guidance for dMMR and pMMR.

The panelists examined the broadening treatment landscape beyond PD-1 inhibitors, highlighting the significant role of trastuzumab in human epidermal growth receptor 2 (HER2)–overexpressing uterine serous and carcinosarcoma subtypes.

Optimizing biomarker testing workflows and pharmacist involvement can improve precision oncology decision-making in non–small cell lung cancer.

New NCCN updates make sacituzumab govitecan a preferred first-line option in metastatic TNBC. Jordan Hill, PharmD, BCOP, explains the impact.

Remote therapeutic monitoring (RTM) improves patient outcomes, reduces hospitalizations, and supports sustainable oncology care delivery.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, from the University of Kansas Cancer Center talks about bispecifics and the value of building a network to communicate operationalizing these therapies across clinics.

Andel's direct-to-employer model partners with Eli Lilly and other pharma companies to offer flexible, insurance-free GLP-1 access that benefits employers, patients, and manufacturers.